Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus Thalidomide in locally advanced HCC
NCT00155272Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2005
- Countries
- 1
01
Overview
Phase 2, open-label trial of thalidomide in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Primary endpoint: Feasibility and tolerability of thalidomide plus radiotherapy. Status: unknown.
02
Drugs
thalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00155272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00155272.